tirzepatide obstructive sleep apnea fda approval 2024 New approved indication for Zepbound In 2024, Zepbound (tirzepatide) became
Description
Peptides to lose weight work by signaling your body to use stored fat for energy
By incorporating Zepbound into treatment plans, healthcare professionals may enhance patient outcomes, particularly since this medication targets the underlying obesity that often exacerbates sleep apnea symptoms
In the US , the American Society of Anesthesiologists (ASA) recommends at least one week , with some surgeons preferring two for extra caution
Lab tests and imaging provide direction without delaying treatment
